Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | IDH1 R132H |
Gene Variant Detail | |
Relevant Treatment Approaches | IDH Inhibitor (Pan) IDH1 Inhibitor IDH1 R132H peptide vaccine PEPIDH1M vaccine |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03343197 | Phase I | Ivosidenib AG-881 | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT05484622 | Phase I | AG-881 AG-881 + Pembrolizumab | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas | Recruiting | USA | 0 |
NCT03893903 | Phase I | Avelumab IDH1 R132H peptide vaccine Avelumab + IDH1 R132H peptide vaccine | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma (AMPLIFY-NEOVAC) | Recruiting | DEU | 0 |
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Recruiting | USA | 0 |
NCT02193347 | Phase I | Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide | IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST) | Unknown status | USA | 0 |
NCT04088188 | Phase I | Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib | Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma | Recruiting | USA | 0 |
NCT02525692 | Phase II | ONC201 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Active, not recruiting | USA | 0 |
NCT04164901 | Phase III | AG-881 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT03224104 | Phase I | Radiotherapy + Zotiraciclib Temozolomide + Zotiraciclib Zotiraciclib | Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) | Completed | FRA | DEU | AUT | 2 |
NCT05609994 | Phase I | AG-881 + PEPIDH1M vaccine | ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas (ViCToRy) | Not yet recruiting | USA | 0 |
NCT04056910 | Phase II | Ivosidenib + Nivolumab | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | Recruiting | USA | 0 |
NCT02977780 | Phase II | CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Active, not recruiting | USA | 0 |
NCT03970447 | Phase II | Lomustine Regorafenib Temozolomide | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE) | Recruiting | USA | FRA | CAN | 1 |